| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Emilio Sacchetti, Alessandro Galluzzo, Paolo Valsecchi, Fabio Romeo, Barbara Gorini, Lewis Warringto. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophrenia research. vol 110. issue 1-3. 2009-07-07. PMID:19269791. |
this 18-week, randomized, flexible-dose, double-blind, double-dummy trial evaluated ziprasidone as an alternative to clozapine in treatment-refractory schizophrenia patients. |
2009-07-07 |
2023-08-12 |
Not clear |
| Emilio Sacchetti, Alessandro Galluzzo, Paolo Valsecchi, Fabio Romeo, Barbara Gorini, Lewis Warringto. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophrenia research. vol 110. issue 1-3. 2009-07-07. PMID:19269791. |
in conclusion, this trial indicates that both ziprasidone and clozapine, having comparable efficacy coupled with satisfactory general safety and tolerability, may be regarded as valuable options for the short-term treatment of difficult-to-treat schizophrenia patients with a history of multiple resistance and/or intolerance to antipsychotics. |
2009-07-07 |
2023-08-12 |
Not clear |
| N N Chitaia, D S Danilov, N A Tiuvin. [Peculiarities of neuroleptic syndrome in women treated with typical and atypical neuroleptics]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 109. issue 3. 2009-06-30. PMID:19365390. |
tolerability of haloperidol, clozapine and risperidone has been studied in 60 women with different psychiatric disorders including schizophrenia (83,2%) and neurotic disorders (16,7%). |
2009-06-30 |
2023-08-12 |
Not clear |
| Seung-Tae Lee, Seunghyong Ryu, Hee Jung Nam, Soo-Youn Lee, Kyung Sue Hon. Determination of pharmacokinetic properties of clozapine and norclozapine in Korean schizophrenia patients. International clinical psychopharmacology. vol 24. issue 3. 2009-06-26. PMID:19194306. |
determination of pharmacokinetic properties of clozapine and norclozapine in korean schizophrenia patients. |
2009-06-26 |
2023-08-12 |
Not clear |
| Ana M Catafau, Marina Suarez, Santiago Bullich, Jordi Llop, Gianluca Nucci, Roger N Gunn, Claire Brittain, Marc Laruell. Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET. NeuroImage. vol 46. issue 2. 2009-06-24. PMID:19233294. |
twenty patients with schizophrenia on monotherapy with risperidone (n=7; 3-9 mg/d), olanzapine (n=5; 5-20 mg/d) or clozapine (n=8; 150-450 mg/d) at stable doses, and ten healthy volunteers (hv) underwent both a [(123)i]ibzm spect and a [(11)c]raclopride pet examinations in random order on different days within a week. |
2009-06-24 |
2023-08-12 |
human |
| Xiaohong Hong, Raymond C K Chan, Xihang Zhuang, Tingyun Jiang, Xiaona Wan, Junqing Wang, Bo Xiao, Hanhui Zhou, Liyun Jiang, Bilan Wen. Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia. Schizophrenia research. vol 108. issue 1-3. 2009-06-16. PMID:19106034. |
p50-evoked potential recordings were obtained from 62 normal controls when they entered the study and from 65 patients with first-episode, never-medicated schizophrenia at baseline and after six weeks of different neuroleptic treatments (sulpiride [n=24], risperidone [n=24] and clozapine [n=17]). |
2009-06-16 |
2023-08-12 |
Not clear |
| Ya-Mei Bai, Jen-Yeu Chen, Tzu-Ting Chen, Chih-Yuan Lin, Pesus Chou, Tung-Ping Su, Chao-Cheng Li. Weight gain with clozapine: 8-year cohort naturalistic study among hospitalized Chinese schizophrenia patients. Schizophrenia research. vol 108. issue 1-3. 2009-06-16. PMID:19150220. |
weight gain with clozapine: 8-year cohort naturalistic study among hospitalized chinese schizophrenia patients. |
2009-06-16 |
2023-08-12 |
Not clear |
| Corrado Barbui, Alessandra Signoretti, Serena Mulè, Marianna Boso, Andrea Ciprian. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophrenia bulletin. vol 35. issue 2. 2009-06-12. PMID:18436527. |
in patients with schizophrenia who do not have an optimal response to clozapine, it remains unclear if there is an evidence base to support a second antipsychotic in combination with clozapine. |
2009-06-12 |
2023-08-12 |
Not clear |
| Corrado Barbui, Alessandra Signoretti, Serena Mulè, Marianna Boso, Andrea Ciprian. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophrenia bulletin. vol 35. issue 2. 2009-06-12. PMID:18436527. |
we conclude that the evidence base supporting a second antipsychotic in addition to clozapine in partially responsive patients with schizophrenia is weak. |
2009-06-12 |
2023-08-12 |
Not clear |
| João Paulo Machado de Sousa, Jaime Eduardo Cecílio Halla. Neurocognitive functioning and facial affect recognition in treatment-resistant schizophrenia treated with clozapine. Schizophrenia research. vol 106. issue 2-3. 2009-06-10. PMID:18845421. |
neurocognitive functioning and facial affect recognition in treatment-resistant schizophrenia treated with clozapine. |
2009-06-10 |
2023-08-12 |
Not clear |
| Dai-Ying Zuo, Yue Cao, Lan Zhang, Hai-Feng Wang, Ying-Liang W. Effects of acute and chronic administration of MK-801 on c-Fos protein expression in mice brain regions implicated in schizophrenia with or without clozapine. Progress in neuro-psychopharmacology & biological psychiatry. vol 33. issue 2. 2009-06-02. PMID:19121361. |
effects of acute and chronic administration of mk-801 on c-fos protein expression in mice brain regions implicated in schizophrenia with or without clozapine. |
2009-06-02 |
2023-08-12 |
mouse |
| Hong Shen, Rui Li, Hong Xiao, Qun Zhou, Qing Cui, Jianfang Che. Higher serum clozapine level is associated with increased antiphospholipid antibodies in schizophrenia patients. Journal of psychiatric research. vol 43. issue 6. 2009-05-13. PMID:18976782. |
higher serum clozapine level is associated with increased antiphospholipid antibodies in schizophrenia patients. |
2009-05-13 |
2023-08-12 |
Not clear |
| Hong Shen, Rui Li, Hong Xiao, Qun Zhou, Qing Cui, Jianfang Che. Higher serum clozapine level is associated with increased antiphospholipid antibodies in schizophrenia patients. Journal of psychiatric research. vol 43. issue 6. 2009-05-13. PMID:18976782. |
this study was to evaluate the relationship between clozapine and apl in schizophrenia patients. |
2009-05-13 |
2023-08-12 |
Not clear |
| L Greenbaum, R C Smith, A Rigbi, R Strous, O Teltsh, K Kanyas, M Korner, D Lancet, E Ben-Asher, B Lere. Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3'-untranslated region. The pharmacogenomics journal. vol 9. issue 2. 2009-05-07. PMID:18347610. |
eps were rated in 184 us patients with schizophrenia (115 african americans, 69 caucasian) treated for at least a month with typical antipsychotic drugs (n=45), risperidone (n=46), olanzapine (n=50) or clozapine (n=43). |
2009-05-07 |
2023-08-12 |
Not clear |
| Gary Remingto. Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms. Evidence-based mental health. vol 12. issue 2. 2009-04-27. PMID:19395610. |
refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms. |
2009-04-27 |
2023-08-12 |
Not clear |
| Vicente Martinez, Martin Sarte. Detection of the moderately beneficial cognitive effects of low-dose treatment with haloperidol or clozapine in an animal model of the attentional impairments of schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 33. issue 11. 2009-04-22. PMID:18094665. |
detection of the moderately beneficial cognitive effects of low-dose treatment with haloperidol or clozapine in an animal model of the attentional impairments of schizophrenia. |
2009-04-22 |
2023-08-12 |
Not clear |
| Vicente Martinez, Martin Sarte. Detection of the moderately beneficial cognitive effects of low-dose treatment with haloperidol or clozapine in an animal model of the attentional impairments of schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 33. issue 11. 2009-04-22. PMID:18094665. |
as this animal model detects the moderately beneficial cognitive effects of haloperidol and clozapine, it may be useful for preclinical research designed to detect and characterize treatments for the cognitive symptoms of schizophrenia. |
2009-04-22 |
2023-08-12 |
Not clear |
| Deanna L Kelly, Heidi J Wehring, Jared Linthicum, Stephanie Feldman, Robert P McMahon, Raymond C Love, Tara Wagner, Joo Cheol Shim, David R Fowle. Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidone. Schizophrenia research. vol 107. issue 2-3. 2009-04-20. PMID:19028422. |
this study examined all available autopsy data on cardiac disease and risk factors in people with schizophrenia in a sample of deceased persons with severe mental illness who had received clozapine (n=62) or risperidone (n=42). |
2009-04-20 |
2023-08-12 |
Not clear |
| Jamie J Layland, Danny Liew, David L Prio. Clozapine-induced cardiotoxicity: a clinical update. The Medical journal of Australia. vol 190. issue 4. 2009-04-09. PMID:19220183. |
clozapine is a valuable drug for patients with treatment-resistant schizophrenia. |
2009-04-09 |
2023-08-12 |
Not clear |
| Armand M Borovik, Martina M Bosch, Stephanie L Watso. Ocular pigmentation associated with clozapine. The Medical journal of Australia. vol 190. issue 4. 2009-04-09. PMID:19220190. |
a 55-year-old woman who was treated with long-term, high-dose clozapine for schizophrenia presented with bilateral decreased visual acuity. |
2009-04-09 |
2023-08-12 |
Not clear |